%0 Journal Article
%T First in human study with a prodrug of galantamine: Improved benefit-risk ratio?
%A Alfred Maelicke
%A Anne C. Baakman
%A Denis G. Kay
%A Ellen 't Hart
%A Erica S. Klaassen
%A Jasper Stevens
%J Archive of "Alzheimer's & Dementia : Translational Research & Clinical Interventions".
%D 2016
%R 10.1016/j.trci.2015.12.003
%X Gln-1062 (Memogain) is a pharmacologically inactive prodrug of galantamine. Owing to its lipophilic nature, it preferentially enters the brain, where it is cleaved into active galantamine. Gln-1062 is expected to have fewer peripheral side effects than other cholinesterase inhibitors, with improved effectiveness
%K Pharmacology
%K Galantamine
%K Donepezil
%K Side effects
%K Alzheimer's disease
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644278/